MCP
MRVI icon

Militia Capital Partners’s Maravai LifeSciences MRVI Stock Holding History

Militia Capital Partners’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-50,000
Closed -$273K – 210
2024
Q4 		$273K Buy
+50,000
New +$322K 0.24% 83

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Militia Capital Partners's MRVI Position: Q1 2025 in Review

Militia Capital Partners sold out of Maravai LifeSciences (MRVI) in Q1 2025, closing a stake of 50,000 shares — an estimated $273K sold.

Militia Capital Partners first reported a position in MRVI in Q4 2024 and held it in 1 quarter. The position peaked at $273K in Q4 2024. 184 funds tracked by Wall St. Rank hold MRVI as of Q1 2025.

  • Militia Capital Partners reported no remaining Maravai LifeSciences position as of Q1 2025 after selling out during the quarter.
  • Militia Capital Partners sold 50,000 Maravai LifeSciences shares in Q1 2025, an estimated $273K.
  • Militia Capital Partners first reported a position in Maravai LifeSciences in Q4 2024 and held it in 1 quarter.
  • Militia Capital Partners's Maravai LifeSciences position peaked at $273K in Q4 2024.
  • 184 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2025.

Based on Militia Capital Partners's 13F filing for Q1 2025, filed 6 Jun 2025.